Free cash flow remains highly unstable, swinging from a 23.6% margin in 2025Q4 to a negative 8.2% in 2026Q1, largely driven by lumpy working capital movements and acquisition-led capital allocation.
| Cash from Operations | 138M | 163.4M | 109.28M | 80.78M | 47.2M | 55.06M | 38.89M | 24.36M | 5.25M |
| Operating CF Margin % | - | 7.7% | 6.29% | 4.87% | 3.48% | 5.7% | 4.76% | 3.1% | 0.8% |
| Operating CF Growth % | -55.17% | 49.53% | 35.28% | 71.17% | -14.28% | 41.57% | 59.66% | 364.05% | - |
| Net Income | 21.76M | 22.92M | 14.38M | 23.08M | -12.06M | -190.65M | 30.9M | 7.95M | -4.19M |
| Depreciation & Amortization | 11.29M | 9.91M | 7.27M | 6.53M | 4.57M | 2.46M | 1.83M | 1.43M | 1.07M |
| Stock-Based Compensation | 18.85M | 0 | 0 | 0 | 67.36M | 253.53M | 484K | 207K | 1.94M |
| Deferred Taxes | 11.69M | 10.87M | 8.82M | 7.46M | -7M | -28.41M | -7.83M | 716K | -258K |
| Other Non-Cash Items | 58.92M | 75.42M | 59.34M | 35.05M | 687K | 157K | 134K | 332K | 147K |
| Working Capital Changes | 14.9M | 44.29M | 19.47M | 8.66M | -6.35M | 17.97M | 13.37M | 13.73M | 6.54M |
| Change in Receivables | -76.89M | -36.67M | -19.82M | -96.88M | -72.2M | -14.64M | -21.78M | -6.18M | 320K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 25.86M | 14.82M | 52.85M | 118.36M | 6.85M | 0 | 4.71M | -4.14M | -983K |
| Cash from Investing | -193.04M | -181.57M | -10.32M | -48.01M | -104K | -32.77M | -380K | -5.71M | -165K |
| Capital Expenditures | -1.23M | -1.2M | -5.02M | -113K | -104K | -547K | -380K | -5.71M | -220K |
| CapEx % of Revenue | 0.05% | 0.06% | 0.29% | 0.01% | 0.01% | 0.06% | 0.05% | 0.73% | 0.03% |
| Acquisitions | -193.16M | -181.72M | -5.3M | -47.89M | 125K | -32.23M | 0 | 0 | 55K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.34M | 1.34M | 0 | 0 | -125K | 0 | 0 | 0 | 0 |
| Cash from Financing | 5.23M | 6.7M | 2.68M | 8.74M | -19.68M | 213.66M | -767K | -10.87M | 15.36M |
| Debt Issued (Net) | -2.46M | -2.46M | 0 | 0 | -33.25M | -875K | -875K | -10.87M | 15.25M |
| Equity Issued (Net) | 6.58M | 8.05M | 2.68M | 8.74M | 13.45M | 223.69M | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.11M | 1.11M | 0 | 0 | 125K | -9.15M | 108K | 0 | 106K |
| Net Change in Cash | -49.81M | -11.46M | 101.64M | 41.52M | 27.41M | 235.94M | 37.74M | 7.78M | 20.44M |
| Free Cash Flow | 136.77M | 162.2M | 104.26M | 80.67M | 47.09M | 54.51M | 38.51M | 18.65M | 5.03M |
| FCF Margin % | 6.09% | 7.64% | 6% | 4.87% | 3.47% | 5.64% | 4.71% | 2.37% | 0.76% |
| FCF Growth % | 15.56% | 55.57% | 29.24% | 71.31% | -13.61% | 41.55% | 106.5% | 270.83% | - |
| FCF per Share | 1.05 | 1.26 | 0.83 | 0.65 | 0.43 | 0.51 | 0.36 | 0.18 | 0.05 |
| FCF Conversion (FCF/Net Income) | 6.28x | 7.13x | 7.60x | 3.50x | -5.50x | -0.29x | 1.24x | 2.95x | -1.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 713K | 888K | 1.93M | 9.2M | 3.72M |
| Taxes Paid | 0 | 0 | 0 | 0 | 307K | 504K | 381K | 316K | 27K |
Working capital volatility
As reported in recent financial statements, PRVA's operating cash flow to net income ratio has fluctuated wildly, ranging from a negative 16.14 in 2026Q1 to a positive 22.59 in 2023Q4, indicating that reported net income is a poor proxy for the company's actual cash-generating capacity.
The extreme divergence between net income and operating cash flow suggests that accounting accruals and the timing of shared savings payments significantly distort the company's reported profitability. Investors should interpret these figures with caution, as the underlying cash reality appears far more sensitive to operational timing than the smoothed net income figures imply.
Based on quarterly filings, PRVA experiences massive swings in working capital, evidenced by an $80.9 million outflow in 2026Q1 following a $99.7 million inflow in 2025Q4, which highlights the lumpy nature of cash collections within the company's value-based care revenue model.
These dramatic shifts in working capital suggest that the company's cash position is highly dependent on the timing of CMS and payer settlements rather than consistent operational efficiency. This volatility warrants further investigation into the predictability of cash inflows, as the current pattern makes short-term liquidity forecasting exceptionally difficult for external observers.
According to historical data, PRVA has prioritized inorganic growth, with net acquisition outflows reaching $92.7 million in 2025Q4, demonstrating a clear preference for deploying capital toward expanding its provider footprint rather than returning cash to shareholders through dividends or buybacks.
The company's aggressive acquisition strategy appears to be the primary engine for its scale-up phase, though it consumes a significant portion of the cash generated during peak collection periods. Investors should monitor whether these acquisitions provide the expected accretive value, as the current capital allocation model leaves little room for error if integration efforts fail to yield anticipated synergies.
As indicated by the provided cash flow data, PRVA's free cash flow margin has swung from a negative 8.2% in 2026Q1 to a positive 23.6% in 2025Q4, reflecting a lack of consistent cash flow generation despite the company's ongoing efforts to scale its physician network.
The erratic nature of free cash flow suggests that the business model is not yet generating the stable, predictable cash flows required to support a mature valuation. This instability may indicate that the company is still in a high-investment phase where cash flow is secondary to the pursuit of market share and provider density.
Quick answers to the most common questions about buying PRVA stock.
Privia Health Group, Inc. (PRVA) generated $163.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Privia Health Group, Inc. (PRVA) generated $162.2M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Privia Health Group, Inc. (PRVA) spent $1.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.